title: Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
authors.affiliation: Department of Urology, Kobe Medical Center, Kobe-shi, Hyogo, Japan. bighill@zeus.eonet.ne.jp.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Oh-Oka
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D053448:Prostatism / Q000188:drug therapy*; D000068581:Tadalafil / Q000627:therapeutic use*
chemical_list: D058891:5-alpha Reductase Inhibitors; D058986:Phosphodiesterase 5 Inhibitors; D018120:Finasteride; D000068581:Tadalafil